Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Endocrine & Metabolic Disease Models

Endocrine & Metabolic Disease Models

In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.
  • DiseaseTypeSpecies
    Obesity and diabetesHigh-fat, high-sugar diet-induced obesity modelMouse/Rat/Hamster
    Streptozotocin-induced diabetes mellitusMouse/Rat
    Spontaneously diabetic mice db/db, ob/obdb/db Mouse,ob/ob Mouse
    ZDF in spontaneously diabetic ratsZDF Rat
    HyperuricemiaPotassium oxyhydrogenate-induced hyperuricemiaMouse/Rat
    Adenine/hypoxanthine + potassium oxyhydrogenate induced hyperuricemiaRat
    Uric acid-induced hyperuricemiaMouse
    Hypoxanthine-induced hyperuricemia in miceMouse
    Adenine + ethambutol-induced hyperuricemia in ratsRat
    Yeast-induced hyperuricemiaMouse
    NAFLD(NAFL / NASH)HFD chow-fed modelMouse/Rat/Hamster
    MCD chow-fed modelMouse
    Compound factor-induced modelRat
    Liver FibrosisTAA-induced hepatic fibrosisRat
    Compound factor approach induced liver fibrosis modelRat
    ConA-induced liver fibrosisMouse
    Porcine serum-induced immunogenic liver fibrosis modelRat
  • What is the Difference Between NAFL and NASH?


    It is completely reversible and can be completely reversed through a healthy lifestyle such as diet and exercise controlling diet, exercise and other healthy lifestyles. Drug therapy is mainly to improve lipid metabolism.


    It is a progressive form of nonalcoholic fatty liver disease, a metabolically stressful metabolic stress liver injury closely associated with insulin resistance and genetic predisposition, can progress to cirrhosis and hepatocellular carcinoma. It was also significantly associated with an increased risk of cardiovascular disease.

    The etiology of NASH is complex, and the exact pathogenesis is unknown. There is no specific treatment or drug therapy for Nash.

    NASH treatment drugs with different targets have become one of the current research and development hotspots, which target the different pathogenesis of NASH, such as liver metabolism, inflammation, oxidative stress, fibrosis, etc.

Relevant laboratories
  • LC/MS
  • centrifuge
  • Pathological observation
  • pathological section
  • frozen slice
  • high-speed centrifuge
  • SPE
  • Liquid analysis laboratory
  • Pharmaceutical laboratory
  • Inspection equipment
  • Immunoassay Platform
Relevant articles